Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 2 of 3 (67%) have an AI response strategy ready • 3 patents granted in the last 365 days
Csl Innovation Pty Ltd. currently has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 3 distinct examiners, including OUSPENSKI, ILIA I, who is the busiest examiner with 1 pending action. The portfolio spans 3 distinct art units, which indicates that the biotechnology and pharmaceutical filings are being evaluated across different specialized technical groups at the patent office.
The distribution of 3 pending office actions across 3 distinct examiners and 3 distinct art units suggests a lack of examiner concentration. Each of the 3 examiners, including OUSPENSKI, ILIA I, handles 1 pending action, requiring counsel to manage 3 different prosecution styles simultaneously. The presence of 3 examiners for 3 pending actions means that no single examiner's preferences will dictate the overall direction of the portfolio. Practitioners must monitor the specific trends in all 3 art units to effectively navigate the 3 pending matters in the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OUSPENSKI, ILIA I | 1 | 77.5% | +20.4% |
| LU, CHENG | 1 | 54.1% | +64.1% |
| MIDDLETON, DANAYA L | 1 | 48.5% | +49.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18004004 | HIGH CONCENTRATION FORMULATION AND USES THEREOF | MIDDLETON, DANAYA L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037219 | METHODS FOR TREATING INFLAMMATORY SKIN CONDITIONS | LU, CHENG | 35d |
| 18037397 | PROTEIN FORMULATIONS AND USES THEREOF | OUSPENSKI, ILIA I | — |
| 18004004 | HIGH CONCENTRATION FORMULATION AND USES THEREOF | MIDDLETON, DANAYA L | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| 1642 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18037397 | PROTEIN FORMULATIONS AND USES THEREOF | OUSPENSKI, ILIA I | 1644 | §102 | Final Rejection | — | AI Ready | May 17, 2023 |
| 18037219 | METHODS FOR TREATING INFLAMMATORY SKIN CONDITIONS | LU, CHENG | 1642 | §103DP | Final Rejection | 35d | AI Ready | May 16, 2023 |
| 18004004 | HIGH CONCENTRATION FORMULATION AND USES THEREOF | MIDDLETON, DANAYA L | 1674 | §103§112 | Non-Final OA | — | Pending | Dec 30, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial